Post-approval studies (Phase 4)Study completedNCT00154362
What this trial is testing
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Who this might be right for
Conduct Disorder
Novartis 50